Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. - Wikidata - awgldk - TriplyDB

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

http://www.wikidata.org/entity/Q40793204

about

Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications Anti-PEG immunity: emergence, characteristics, and unaddressed questions.Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity.A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties Pre-existing Antibody: Biotherapeutic Modality-Based Review.Extracorporeal delivery of a therapeutic enzyme.Urate-lowering therapy: current options and future prospects for elderly patients with gout.Advances in pharmacotherapy for the treatment of gout.Enzymes approved for human therapy: indications, mechanisms and adverse effects.Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.The safety of treatment options available for gout.Recent advances in understanding and managing gout Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol.PEG-ing down (and preventing?) the cause of pegloticase failure Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.Lesinurad for the treatment of hyperuricaemia in people with gout.Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.Sensitive and Quantitative Detection of Anti-Poly(ethylene glycol) (PEG) Antibodies by Methoxy-PEG-Coated Surface Plasmon Resonance Sensors.Recent pharmacological advances in the management of gout.Physician Awareness of Immune Responses to Polyethylene Glycol-Drug Conjugates.Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer.Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.Impact of pegloticase on patient outcomes in refractory gout: current perspectives

P2860

Q26738948-1E055860-2E5D-4FC0-9698-0B85D3ADE49B Q26825556-B6AB4DCB-0CFB-4AB1-B8F2-8472EFD4FDB8 Q27000048-6726084B-1B18-40C8-83CF-86B188BAFA25 Q36120371-42935454-5BDA-4AE1-87BE-04592BF0099B Q36230423-7CA8B34A-AA40-4C6A-AEBF-15200EFC00E1 Q36653888-A90CBE59-F588-4D99-B00D-8BDD811120C2 Q37141213-C0568C54-4938-4D00-98F9-8F0F033B29DF Q38254304-3F0DF75E-FB78-4E4C-984F-0170360478E6 Q38303416-6A09836D-DC5A-48E2-8911-0003B65AF21B Q38342838-7C241DD3-00DA-47ED-BE2A-81AD240C6B31 Q38704139-5508A4E9-59F0-4C9F-BBCB-96B67D292ED8 Q39092018-7C0FF4E3-7E0E-49A3-A477-169DADEE1ABB Q39207801-CEDCD8EA-869A-42F5-861E-E9E133DEFAA3 Q40089636-0DA593C1-EDD6-4579-AC4F-3FB97C4FF5A1 Q41196820-009C8047-D10C-4092-BCA8-F3E31860C9F5 Q42699501-6F7F5B88-395F-4024-A7E1-81CFE8CA767B Q45873829-6C9A933E-6AF6-41D2-85B5-AE8647F9384D Q47102857-ADC2B147-2771-42B5-A74D-F26FCFF06135 Q47104100-48689E2E-C367-4B3B-AF54-2A5832DE2077 Q47657420-7A17101D-BFC9-442B-A00F-9A5ED4DAD786 Q47690427-98BF4329-0837-4BBE-ABB6-7C091AAE9452 Q47902077-3C5AC3B9-61D7-4702-9C43-3375100B81E4 Q47919692-A61B5BD5-4780-4A23-AAE3-181721F75322 Q49565303-F48EC487-F26D-4219-8C07-B3AB7C55CC09 Q50285020-EFE0D811-F573-4410-A40E-5430275446B9 Q51602149-E7E405C2-E4E1-4724-BC81-533AA01D9731 Q58698860-4FA0C83C-BAB2-45D3-8FAA-20772FA9BC37

P2860

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

http://www.wikidata.org/entity/Q40793204

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Pegloticase immunogenicity: th ...... d for refractory chronic gout.

@en

type

label

Pegloticase immunogenicity: th ...... d for refractory chronic gout.

@en

prefLabel

Pegloticase immunogenicity: th ...... d for refractory chronic gout.

@en

P1433

Q40793204-A028815C-2EF3-4CBD-8E56-651A8BD526D6

P1476

Q40793204-0523533A-8D24-475E-BBF7-2D31C5B9BEE1

P2093

Q40793204-03CB0F00-31E7-46A7-99A6-B9A00535C7FA

Q40793204-8E2699DD-BDCC-4C75-B55A-3A1CE6034FE8

Q40793204-97103BF6-9243-4C90-8F56-2BC099C24CBF

Q40793204-A553C48B-048A-4595-86F9-E13F853B60F3

Q40793204-B87D068A-B64D-4516-86CE-AF0B9F726E0E

Q40793204-E5E01C73-79BC-4A5C-A2CE-226AB97F44FC

Q40793204-F80C8065-D742-4716-93F2-FEA60F9F0F31

P2860

Q40793204-05276CA3-342F-4D19-8DCB-36217E1CB58C

Q40793204-170D717B-61C6-4C53-9133-0D3B487A0ED7

Q40793204-1F745AB9-4CEA-4CB9-9C2F-307B1FDD4785

Q40793204-2F88221C-F4BC-4ABC-A193-ECD26214CB25

Q40793204-2FCF8316-6689-4528-BE46-BAB372BA339D

Q40793204-54238589-B8A5-4E07-B151-DD43859E6681

Q40793204-88745A57-DE34-414F-AE8F-F3025608DF22

Q40793204-9200AA6D-0C30-4CEA-B6FE-D57CDFE5A0D4

Q40793204-A2C83686-389A-4E8E-96DD-BAF7809CD9EA

Q40793204-BD2E30A4-B070-4C72-B1D4-02F853B7765B

P2888

Q40793204-10183AAA-1EA3-4535-AD2E-B623BAD17844

P304

Q40793204-9BD4FB2E-12A0-4ADB-AFC5-6C21515AF6F0

P31

Q40793204-3D9D8E74-7D53-4CCB-8E31-B34C2F5D7BA1

P356

Q40793204-79B3A3DA-54B4-4A17-AB9E-B4A5B0AA3E9D

P433

Q40793204-E4E77C8A-40F9-48BB-82C7-59578005D2E4

P478

Q40793204-80FEB3BF-ADCC-4B31-AF0B-478127FEFBCB

P577

Q40793204-EB838D00-D9DD-4F78-88FA-4B3A66E344C6

P5875

Q40793204-43C80BD4-D64E-45E7-A117-03915F3D3AE5

P698

Q40793204-A3627370-8220-4AE7-A455-BF2BBD007FE5

P932

Q40793204-90150203-B811-4A28-9080-8C84E47C72F2

P356

P1433

Arthritis Research and Therapy

P1476

Pegloticase immunogenicity: th ...... d for refractory chronic gout.

@en

P2093

Arthur Kavanaugh

http://www.w3.org/2001/XMLSchema#string

David Wright

http://www.w3.org/2001/XMLSchema#string

John S Sundy

http://www.w3.org/2001/XMLSchema#string

Leonard H Calabrese

http://www.w3.org/2001/XMLSchema#string

Marsha Wolfson

http://www.w3.org/2001/XMLSchema#string

Michael A Becker

http://www.w3.org/2001/XMLSchema#string

Peter E Lipsky

http://www.w3.org/2001/XMLSchema#string

P2860

Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.

The impact of PEGylation on biological therapies.

Clinical manifestations of hyperuricemia and gout.

Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged.

Delivery of therapeutic proteins.

Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation.

P2888

P304

R60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR4497

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260484125

http://www.w3.org/2001/XMLSchema#string

P698

24588936

http://www.w3.org/2001/XMLSchema#string

P932

4060440

http://www.w3.org/2001/XMLSchema#string